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ABSTRACT
Effectiveness of Pathogen-Specific Passive Antibodies to Mitigate Infectious Diseases in
Apis Mellifera
Tanner Nordseth
Director: Benjamin Hause, Ph.D.

Honeybees (Apis mellifera) are widely recognized as a vital part of the global
ecosystem and the world's food supply due to their pivotal role in the pollination of both
natural and agricultural flora. Colony Collapse Disorder (CCD) is an emerging
phenomenon characterized by a colony's worker bees deserting the hive and leaving the
queen behind. This usually results in colony failure. CCD is a multifactorial issue, with
many environmental stressors and pathogens playing a role. Deformed Wing Virus
(DWV) has been identified as a leading cause in this phenomenon. Paenibacillus larvae
(P. larvae) is another lethal pathogen that is responsible for American Foulbrood Disease
and can also ultimately lead to colony collapse. Honeybees have ineffective innate
immunity against these pathogens and lack an adaptive immune system altogether.
In the research being presented, novel passive antibody therapy was used to treat
DWV and P. larvae. To develop this therapeutic, white leghorn hens, which are known
to confer passive immunity to the yolks of their eggs in the form of Immunoglobulin Y
(IgY), were vaccinated against one of these antigens. The egg yolks were harvested,
diluted, and purified to produce concentrated IgY specific to either DWV or P. larvae.
This purified IgY was added to the larval diet and orally administered to 1st instar larvae

in a challenge study to test its ability to protect against either DWV or P. larvae
challenge. Experimental results revealed that among larvae challenged with DWV,
mortality dropped from 79% to just 29% when a 1:100 dilution of DWV-specific IgY
was administered. Likewise, larvae challenged with P. larvae saw mortality drop from
100% to only 17% when treated with a 1:100 dilution of P. larvae-specific IgY. The
mortality trends in both models were supported by corresponding molecular data in the
form of either RT-PCR or CFU/mL data. These results suggest that pathogen-specific
IgY may provide honeybee larvae with approximately 50% protection against lethal
DWV disease and 80% protection against lethal P. larvae disease – figures that would
significantly reduce CCD. This technology could have a profound impact on the future
of beekeeping – an industry that is key to avoiding a global food sustainability crisis.

KEYWORDS: Deformed Wing Virus (DWV), Colony Collapse Disorder (CCD),
Immunoglobulin Y (IgY), honeybees, Apis mellifera, Paenibacillus larvae (P. larvae)
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CHAPTER ONE
Introduction

Agricultural and Economic Significance of Apis Mellifera
Originating in East Asia, the western honeybee (Apis mellifera) is widely
renowned as perhaps the single most important organism for maintaining agricultural
sustainability and biodiversity among flowering plants.1,2 Bees are responsible for the
pollination of more than 400 commercially grown agricultural plants and approximately
1/6 of the world’s natural flowering plants.3 Unlike other pollinators, A. mellifera is
considered a “generalist forager” because it visits such a wide array of plants.4 Honeybee
colonies are rented around the globe for the production of hive products (i.e. honey) and
pollination services (90% of commercial pollination occurs via A. mellifera), making this
one of the most economically important insects.2,5 Crops such as almonds are entirely
dependent on A. mellifera for pollination; blueberries and cherries are approximately 90%
dependent; and nearly every other fruit, nut, vegetable, melon, and field crop produced in
the United States is at least partially dependent upon the honeybee.6,7 Today, there are
approximately 2.7 million A. mellifera colonies in the United States, with over 1.8
million in California alone to support the state’s almond industry.7 In recent decades,
honeybees are also steadily increasing their value contributed to the agricultural
economy, with their pollination services and honey products contributing an estimated
$9.3 billion in 1987, $14.6 billion in 2000, and $20 billion in 2020 to U.S. crop
production.6,7
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Colony Collapse Disorder
In recent years, A. mellifera has become increasingly afflicted by Colony Collapse
Disorder (CCD), a multifactorial phenomenon that induces the swift demise of an entire
colony. CCD is best characterized by the rapid disappearance of a colony’s adult worker
bees, leaving behind a seemingly healthy colony containing food, brood, and a queen.8
As the honeybee population continues to dwindle, it has been surmised that malnutrition
from a decrease in flower diversity and the increase in pesticide usage, especially
neonicotinoids, are two likely contributors.9,10 There is also evidence suggesting that the
rise in global CO2 levels may be causing fundamental alterations in the physiology of
pollen-producing plants that diminish the pollen’s protein content and create nutritional
deficits for A. mellifera.11 There is ongoing debate regarding which of these factors are
most problematic and what steps should be taken to protect A. mellifera. While each of
these factors likely creates strain on the honeybee population, a pathogen known as
Deformed Wing Virus (DWV) is widely considered to be the predominant stressor
contributing to CCD.

Overview of Deformed Wing Virus
DWV is a critical honeybee pathogen that has captured the attention of
apiculturists in recent years. The discovery of DWV began with the isolation of Egypt
Bee Virus, a virus now known to be related to DWV that was isolated from asymptomatic
adult worker bees in Egypt in 1977.12 This discovery inspired further study of honeybee
virology, and in 1982 a virus distantly related to Egypt Bee Virus was isolated in Japan. 12
This virus was temporarily termed the Japanese Isolate of Egypt Bee Virus, but was
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quickly renamed for the characteristic symptoms it caused and given its present-day
name: Deformed Wing Virus.12
DWV is the most widespread of all honeybee viruses, affecting 50-75% of
colonies across the world.10 This virus can act as a devastating long-term stressor to a
hive at both the individual and colony levels, causing both CCD and increased winter
mortality losses.10,13 At the individual level, the classical symptoms of DWV infection in
adults include, but are not limited to: shrunken and crippled wings; disfigured or
discolored abdomens; protruded proboscis; and incomplete development of the
hypopharyngeal glands and mandibular glands.14 In larvae, pupae, and emerging pupae,
infected individuals exhibit significantly higher mortality rates before capping, during
pupation, and during emergence from capped brood cells; slower emergence from capped
brood cells; and lower body weights.14,15 Infections are not always overt; covert
infections are the most common and occur when the viral load threshold to display visible
morphological symptoms is not reached.10 Covert infections have long manifested
themselves in hives without causing extensive damage to colonies; severe overt
infections are a mostly modern development. For an infection to be considered covert, it
must meet three criteria: presence of viral material without symptoms of disease, spread
via vertical transmission, and the occurrence of sporadic overt outbreaks. 12 Covert
infections are also detrimental, leading to issues such as cognitive impairments,
accelerated life cycle behaviors, increased rate of cellular apoptosis, and reduced life
expectancy.10,14 There are also disputed claims that covert DWV infection may lead to
shortened flight duration and distance during foraging.10 Individuals with visible overt
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infections have a significantly higher viral load than their unaffected counterparts,
containing a factor of approximately 1.7 x 106 more virus particles.14
At a colony level, individuals with both overt and covert DWV infections
contribute to elevated hive mortality rates and ultimately CCD. Individuals with
morphological symptoms of the wings, abdomen, and proboscis may have compromised
flight, digestive, and feeding abilities – all of which contribute to early mortality. The
implications of covert infections can also be highly deleterious.10 These individuals often
demonstrate behaviors earlier in their life cycle than what is natural, especially
precocious foraging, or premature foraging, which is the natural response of bees under
stressful conditions and is considered a risky behavior.10 As these individuals live an
abbreviated life, their total activity and contribution to the hive is also reduced.10
Precocious foraging is also disruptive inside the hive, as bees demonstrating accelerated
behavioral maturation spend less time in the nursing phase before beginning to forage,
leaving a suboptimal number of individuals left tending to the brood and thus further
accelerating colony collapse.10 Both covert and overt infections can lead to neurological
maladies including sensory defects, upregulation of the immune system, and memory
deficits.10

Structure and Classification of Deformed Wing Virus
DWV belongs to the genus Iflavirus within the family Iflaviridae.12 The virus
consists of a single-stranded, positive-sense RNA genome (+ssRNA) that produces a
non-enveloped virion 30 nm in diameter with icosahedral geometry and three major
structural viral proteins: VP1, VP2, and VP3.12,14,16 In general, all strains of DWV have
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the following basic genome organization: a long 5’ untranslated region (5’ UTR)
containing an Internal Ribosome Entry Site (IRES), a single open reading frame (ORF) in
the middle, and a short 3’ UTR that is highly conserved and terminates with a 3’ poly-A
tail.12,17 It is believed that the IRES makes it possible for the virus to avoid and/or disrupt
the host organism’s cap-dependent mRNA translation system.17
Currently, there are two main strains of DWV described: Type A and Type B,
which are believed to have diverged from each other around the year 1835.2,18 There is
also emerging evidence of a Type C variant that diverged around the year 1697.18 These
strains differ slightly in geographic distribution and Type B has been found to be more
virulent.2,10 Despite these slight regional variations, the DWV genome sequence is highly
conserved and largely consistent throughout the world and among all strains.4 DWV is
closely related to Kakugo Virus (KV) and Varroa Destructor Virus 1 (VaDV-1), two
other iflaviruses that affect honeybees.4 Due to the 97% sequence homology between
DWV and KV, there is ongoing research to determine whether these viruses are separate
species or simply regional isolates of the same species.4

DWV Transmission and Infection
The primary mechanism of DWV transmission is via the parasitic Varroa
destructor mite, a natural host of the virus.13,14 This mite serves as both a biological
vector that supports the replication of DWV before transmission and a mechanical vector
that circumvents the A. mellifera physical defense barriers by injecting the virus directly
through the exoskeleton and basal lamina of the epithelia and directly into the
hemolymph.1,19 While Varroa mites serve as the most common and infectious vehicle of
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DWV transmission, once the virus is present in a colony it can also be spread by infected
A. mellifera via horizontal transmission (intra-generational) and vertical transmission
(inter-generational).12 Vertical transmission of DWV occurs when infected parents
produce infected offspring due to the presence of DWV in the sperm and/or egg gametes.
Horizontal transmission of DWV occurs when the virus is spread between individuals
from fecal matter, cannibalization, or orally via trophallaxis. 12,19 Active infection is best
identified by detecting viral proteins and nucleic acid species produced during DWV
replication via RT-PCR.12,20
The mechanism of entry into host cells for iflaviruses is believed to resemble that
of the related family of picornaviruses, which utilize receptor-mediated endocytosis.16
To enter endosomes, virions must be exposed to a solution of sufficient pH or ion
concentration that initiates the detachment of the P domain at the C-terminal of VP3.16
DWV’s P domain contains a catalytic triad of the residues Asp294, His277, and Ser278.16
These residues are structurally flexible, and it is hypothesized that when in the optimal
conformation, this triad catalyzes hydrolytic reactions that allow the P domain to bind to
virus receptors or disrupt the membrane in a fashion that makes it possible for the virus to
inject its +ssRNA genome into the host cell’s cytoplasm and infect the cell.16
Once an A. mellifera host is infected, DWV infection has a high degree of tissue
specificity.19 DWV RNA can be found in the brain, midgut epithelium, gut contents, and
reproductive organs.4,19 Viral loads are highest in the reproductive organs; the testis and
seminal vesicles of drones and the ovaries of queens.19 High viral loads in drones’
reproductive organs can hinder their reproductive fitness and cause them to transmit
DWV RNA through their sperm, thus contaminating the queen and contributing to the
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vertical transmission of DWV to the next generation of workers. 19 DWV can also be
found in multiple regions of the brain of infected A. mellifera, especially the corpora
pedunculata neuropils, or mushroom bodies, where DWV actively replicates. 4,10 These
structures serve as important higher brain centers that are largely responsible for olfaction
and other sensory processes.4 DWV infection of the mushroom bodies likely contributes
to issues with olfaction, vision, and possibly even behaviors that promote the horizontal
transmission of the virus to nearby colonies.4,10 DWV has also been associated with
memory loss, learning defects, and poor orientation abilities, making infected individuals
more susceptible to predators.10
A. mellifera has limited innate immunity against DWV and largely ineffective
defense mechanisms against Varroa destructor and the spread of the virus. Unlike Apis
cerana, the eastern honeybee and original host of Varroa, A. mellifera cannot combat
varroosis by temporarily suspending worker reproduction or entombing infested drone
brood, processes which have shown to reduce the number of viable hosts for Varroa and
reduce mite prevalence by up to 25% in A. cerana.21,22 Instead, the A. mellifera mite
defense strategy relies on grooming and hygienic activity.21,23 Grooming is a behavior
where bees inspect and clean their bodies to remove any foreign material, including
mites. Bees may perform this task on themselves (auto-grooming) or on other individuals
in the colony (allo-grooming).24 Hygienic behavior describes the removal of dead,
defective, diseased, or infested brood prior to emergence as adults.13 Colonies that
demonstrate high performance in grooming and hygienic behaviors represent the most
attractive candidates for the selective breeding of mite-resistant honeybees.13 There is
also evidence that A. mellifera selectively bred for the trait “Suppression of Mite
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Reproduction” (SMR; a variety of behaviors and detection mechanisms that result in
heightened sensitivity to cues associated with mite-infested pupae) remove an even
greater amount of mites than those bred for only hygienic activity.25 SMR bees may also
induce physiological changes in Varroa that reduces the mites’ fertility and offspring
viability.25 This ability comes with a steep tradeoff, however, as this same factor is also
believed to hinder pupal development and reduce overall brood viability.25 Despite these
attempted defensive measures, this host-parasite relationship is unbalanced and A.
mellifera is still largely unequipped to effectively combat the invasive Varroa mite and
ensuing DWV infection.13

Varroa Destructor Mites
Varroa destructor is a hematophagous ectoparasitic mite that poses a serious
threat to modern apiculture.13 This invasive species was spread to A. mellifera in Europe
from its original host of A. cerana in Asia as domesticated honeybees were transported
throughout the world during the 20th century, particularly the 1970’s and 1980’s.12,13
Today, the only remaining Apis colonies free from Varroa exist in Australia and a few
remote, isolated islands.26 Apis mellifera is the only Apis species that does not naturally
host a parasitic mite in its brood, making it especially susceptible to invasive mite species
such as Varroa.26 Varroa is best known for its association with the transmission of DWV
to honeybee colonies via feeding behavior, the most destructive consequence of
varroosis.
While DWV is occasionally found in colonies free of Varroa, the virus is detected
in just 6-13% of colonies without the mites and in 75-100% of colonies infested by the
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mites.1,2 Viral load is also greatly amplified by the presence of these pests; there is a onemillion-fold difference in viral load between colonies with Varroa compared to those
without Varroa.1,2 The seasonal levels and distribution of DWV also closely match the
seasonal prevalence of Varroa, with levels climbing during the late summer.12 While
varroosis increases the viral load of DWV in a colony, it decreases the variant diversity.2
It is believed that Varroa selects for the DWV strains with competitive advantages that
cause them to be the most virulent and persistent in the local A. mellifera population.2 It
should also be noted that for a mite to cause an overt infection, it must be both a
mechanical and biological vector of DWV that produces a high enough viral titer to reach
the threshold of disease via transmission.27 Mites that are capable of causing wing
deformities contain 102 to 104 more DWV particles than mites that are not.14
When left untreated, most colonies will collapse from varroosis in 2-3 years.13
Much like the associated DWV infection, Varroa infestation damages A. mellifera at both
the individual and colony levels. Varroa is capable of injecting viral material and
salivary proteins that activate latent infections present from vertical transmission directly
into the hemolymph of its host.28 It also consumes a significant amount of the host’s
hemolymph throughout all life stages.13 This loss of hemolymph in adult honeybees
weakens them and causes immunosuppression, but it is especially detrimental when it
occurs during the larval and pupal stages.13 When parasitized by Varroa during the
developmental stages, worker and drone brood that survive the pupal phase will emerge
with a reduced body weight and likely display symptoms of overt DWV infection.15 The
presence of just one adult female mite in a brood cell and her progeny that begin feeding
during the pupal phase can reduce emergence weight of adult drones by 10%.15 At the
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colony level, Varroa inhibits colony reproduction by reducing the reproductive fitness of
drones.28 As less reproduction occurs and more workers die from DWV infections, the
colony’s overall foraging activity decreases, leading to a depleted nectar and pollen
supply.10 Additionally, colonies affected by varroosis exhibit less swarming.29
Sometimes referred to as colony fission, swarming is the mechanism through which an
entire colony reproduces by splitting one colony into two. 29
The Varroa life cycle is divided into two major phases: phoretic and
reproductive.13 During the phoretic phase (sometimes referred to as the dispersal phase)
mites attach to mature A. mellifera and travel with them as they forage, offering them a
means of transportation to spread beyond the colony.13 Varroa much prefers the dark,
humid climate inside the hive – especially within sealed brood – so the dispersal that
occurs during the phoretic phase marks the only time Varroa leaves the colony during its
life cycle.13 During the reproductive phase, Varroa focuses its efforts on a colony’s
brood.13 This phase begins when mites enter worker and drone brood cells just prior to
capping (t = 7-8 days after A. mellifera eggs are laid).13 Mites preferentially choose cells
that are shallower, wider, older (contain more residual semiochemical attractants from
larval food and cocoons), and contain the largest larvae (preferably 5th instar).30,31 Next,
they crawl to the bottom of the cell where they “hide” beneath the larvae in the larval
feed to avoid detection by hygienic bees until capping occurs.13 After capping, mites
feed on pupal hemolymph while undergoing oogenesis and vitellogenesis.13 Mite eggs
are laid about 70 hours after capping occurs and will develop into adult Varroa in
approximately six days.13 Finally, both parent and progeny emerge from the brood cell
with the adult bee when pupation is completed (for workers, t = 20-21 days after A.
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mellifera eggs are laid; for drones, t = 24 days).13 Some may remain attached to the
emergent bee while others will scatter throughout the colony. Of those that scatter,
Varroa females can detect age and function of bees in the colony, and they methodically
seek out middle-aged nurse bees to transport them to brood cells around the hive.13
During reproduction, Varroa are believed to prefer drone brood over worker
brood due to drones’ longer pupation period.13 With the additional 3-4 days to feed and
reproduce while pupae are capped, mites in drone cells will produce approximately 1.6
times more mature female offspring than their counterparts in worker cells.13 Varroa’s
tendency to thrive in brood cells with longer pupation periods may also contribute to A.
mellifera’s elevated susceptibility to Varroa compared to A. cerana, a species with
slightly shorter larval and pupal periods. Given this preference, it is estimated that drone
brood have an 8-10-fold higher rate of infestation than worker brood. 30 This may also be
due in part to the more intensive and frequent tending that drone brood receives, allowing
more opportunities for mites on nurse bees to reach 5th instar drone larvae.30 Varroa
females are able to identify their preferred targets due to their attraction to methyl and
ethyl esters of straight-chain fatty acids, brood pheromones present in the larval cuticle
that stimulate capping of the brood cell.32 These esters are inherently higher in drones
and 5th instar larvae.32 Mites are highly sensitive to changes in these pheromones; the
variation in ester hydrocarbon structure between 4th and 5th instar larvae elicits a strong
preference for 5th instar larvae.31 Unlike worker and drone brood, queen brood show an
exceptionally low rate of Varroa infestation.33 This is likely explained by both the
shorter pupation period of queen brood and the presence of octanoic acid in queen larvae
and queen extracts, a compound known to be repellent to female Varroa.13,33

11

American Foulbrood and Paenibacillus Larvae
Paenibacillus larvae (P. larvae), formerly known as Bacillus larvae, is a Grampositive and spore-forming bacterium that causes the disease American foulbrood (AFB)
in A. mellifera.34,35 The bacterium has a rod (bacillus) shape, rounded ends, a length of
2.5 – 5.0μm, a width of approximately 0.5μm, and often grows in elongated chains.36
This facultative anaerobe produces highly infectious spores and it can be found in most
parts of the world and in all castes within infected honeybee colonies.34,37 Previously, P.
larvae was separated into two subspecies, Paenibacillus larvae larvae and Paenibacillus
larvae pulvifaciens.38 However, a 2006 taxonomic review supported the merger of the
two subspecies into one species based on biochemical profiles and spore morphologies.38
There are currently four strains of P. larvae that have been identified to cause AFB,
labelled ERIC I-IV based on their enterobacterial repetitive intergenic consensus (ERIC)
sequences.39 ERIC I is found worldwide, while ERIC II is found only in Europe and is
considered the most virulent strain, as it is capable of killing all larvae in a hive within
seven days of infection.39 P. larvae produces the toxin C3larvin, which possibly
contributes to AFB pathology.39
AFB affects a colony’s brood and is characterized by disproportionately high
mortality among larvae and pupae, while adults are not susceptible to the disease.5 A
larva must only consume a few spores within the first 36 hours of life post-hatching for
infection to begin.39 Given the severe pathology of the brood, AFB is currently the most
damaging and economically relevant bacterial disease facing honeybees as it is ultimately
lethal to the entire colony if left untreated.5,34 Much like DWV, AFB can be transmitted
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both horizontally, as bees travel throughout their colony, and vertically. Vertical
transmission can occur at either the individual level when an infected queen or drone
passes the virus to offspring during reproduction, or at the colony level when an infected
colony swarms to “reproduce” or create a new colony. This disease is listed in the
Terrestrial Animal Health Code through the World Organization for Animal Health,
setting many strict recommendations on foreign honeybee importation to prevent further
spread of this disease.34,40
P. larvae and AFB clinical infections can be easily identified in a hive by
assessing the distribution and appearance of larvae in areas containing brood. Hives
suffering from AFB will display empty or discolored spots within brood regions due to
brood cells that are empty or contain dead or dying larvae.35 Diseased hives also produce
significantly less honey than their healthy counterparts.41 Clinical symptoms of infected
brood include discoloration, a characteristic foul odor, and brown remains with a
gelatinlike consistency.35,38 Freshly deceased, these remains are stringy and form ropelike strands when prodded.38 During decay, these remains will shrivel into solid scales
containing millions of active P. larvae spores that cling to the bottom and sides of brood
cells.38 Each infected larva may produce anywhere from 1 billion to 2.5 billion
spores.36,40 These scales are so firmly adhered to the brood cells that they are largely
resistant to hygienic honeybee behavior, leaving them in place to release spores and
ultimately infect the next larva that occupies the cell. Spores can remain active inside a
hive for at least 35 years.42 Subclinical infections must be diagnosed in a laboratory
setting, where the presence of P. larvae is confirmed via microscopy and/or culture.35,40
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Treatment of AFB is difficult given P. larvae spores’ extreme heat and chemical
resistances.40 The pathogen has also developed resistance to many commonly
administered antibiotics such as oxytetracycline (the most common AFB antibiotic of the
last 50 years; commercially known as Terramycin and produced by Pfizer), which is the
only antibiotic currently approved by the United States Food and Drug Administration for
AFB treatment.5,43 Oxytetracycline aims to thwart P. larvae spore germination until
brood have passed the age of highest vulnerability while also buying the colony time to
remove already dead or diseased brood.43 While some antibiotics can effectively
neutralize vegetative P. larvae, they still fail to treat spores and ultimately fail to prevent
the recurrence of AFB.35 To prevent the spread of the pathogen, it is therefore common
practice to destroy diseased colonies, usually by burning them and the equipment
associated with them.5,35 Artificial swarming is also an option, a practice that involves
prompting adult bees to relocate to a new hive and leave behind the diseased brood,
which can then be destroyed.44 Finally, colonies that are selectively bred for increased
hygienic behavior in nurse bees have displayed a significant reduction in AFB prevalence
and a much higher recovery rate.41 Spores, the agents of AFB infection, begin appearing
in diseased brood cells 10-11 days after eggs hatch when 5th instar larvae are developing
into prepupae.41 Sporulation occurs when the prepupae succumbs to the infection, so it is
critical to the survival of the hive for hygienic bees to remove diseased larvae as quickly
as possible.45 Remarkably, data shows that P. larvae strains that are more virulent to
individual larvae are less virulent to the overall colony, as the diseased larvae die faster
and hygienic bees can remove them faster, leaving less time for bacterial propagation.46
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Immunoglobulin Y
Immunoglobulin Y (IgY) is a newly utilized antibody with broad therapeutic
capabilities to combat many pathogens.47 This antibody was first described in 1983 and
began to be applied for practical applications in the 1990’s. 48 IgY can be found in the
egg yolks of reptiles, amphibians, and most notably birds – specifically chickens.48 This
avian antibody is a result of passive immunity, as IgY is transferred from the maternal
blood serum to egg yolks to protect developing embryos from the vertical transmission of
pathogens throughout embryogenesis.48,49 Maternal IgY also functions to provide
protection to offspring early in life while the immune system matures and generates
immune effectors.
IgY has a great deal of industrial appeal, as chickens can efficiently produce
highly specific antibodies against a multitude of pathogens beyond just avian species. 50
Hens may be vaccinated with an antigen to produce IgY against the antigen of interest or
with gene expression vectors to produce IgY with specificity for the given gene.48
Evidence suggests that hens produce maximal IgY specific to the antigen or gene of
interest when they are immunized intramuscularly in the pectoral muscle tissue as
compared to receiving the immunization subcutaneously.51,52 At peak immunity, 2-10%
of hens’ total IgY production will be specific to the antigen or gene of interest from the
immunization.53
Some of the main advantages of IgY include its relative ease of mass production,
the non-invasive manner in which it is collected, and its enhanced response to
mammalian antigens.50 Mature eggs contain 100-200 mg of IgY when they are laid, and
one laying hen produces an average of 40 g of IgY per year.48,50 There have been several
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strategies developed to efficiently extract IgY suitable for biomedical use. Mammalian
IgG and other types of passive antibodies have historically been utilized for such
biomedical purposes, which required bleeding of hyperimmunized animals to harvest
antibodies.48 Using the IgY of chicken egg yolks represents a far more ethical, more
cost-effective, and less invasive means of antibody extraction than the traditional
practices of IgG collection.48 There is also evidence that chickens can produce higher
titer antibodies against mammalian antigens than other species vaccinated against these
same antigens.50 This is due to the increased phylogenetic distance between chickens and
mammals, as immune response increases as the evolutionary gap increases between
antigen host species and immunized species.50,54
IgY has the classic “Y” antibody shape and consists of the standard two identical
heavy chains and two identical light chains that are connected by disulfide bonds. 55
These chains consist of constant domains and variable domains that make up antigenbinding fragments (FABs) that bind specific antigen sequences. Light chains are
comprised of one variable domain and one constant domain. Heavy chains consist of one
variable domain and four constant domains (CH1, CH2, CH3, CH4).54 Perhaps the most
prominent and unique structural feature of IgY is its lack of a hinge region, making it
more rigid than mammalian immunoglobulins, including IgG.54 This lack of flexibility is
caused by glycine and proline residues between the CH1, CH2, and CH3 constant
domains.55 It is believed this extra rigidity contributes to the functionality of IgY. This
includes IgY’s inability to agglutinate polyvalent antigens in normal conditions, likely as
a result of the inability to achieve the required conformation of the FABs due to steric
hindrance.55 IgY has a molecular weight of approximately 180 kDa.55
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CHAPTER TWO
Materials & Methods

Vaccination of Chickens and Yolk Collection
Six white leghorn chickens, approximately 6 months of age, were immunized four
times with 10 µg each of purified DWV VP1, VP2, and VP3 proteins in phosphate
buffered saline along with incomplete Freund’s adjuvant at 67% (v/v). The DWV
proteins were expressed as hexahistidine-tagged fusion proteins in baculovirus and
purified using affinity chromatography by Genscript. An additional six birds of the same
age were also immunized four times against P. larvae. These vaccinations consisted of
spores cultured from P. larvae obtained from the American Type Collection Collection
and grown on 5% sheep blood agar for seven days. Spores were recovered by scraping
the plate overlaid with 5 mL of PBS. Spores were inactivated with formalin.
The birds were vaccinated with a 0.5 cc intramuscular injection in each breast.
Immunizations were given periodically at 21-day intervals to sustain the immune
response and trigger the immunized hens to continue passively generating pathogenspecific antibodies in their eggs. Eggs were collected daily, beginning two weeks after
the third vaccination. Yolks were separated from the albumen using a wire egg
separating apparatus. The yolks were pooled and refrigerated until further processing.
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Figure 2-1. Separated egg yolks from hens vaccinated against DWV and P. larvae.

Figure 2-2. Visualization of IgY experimental concept.56 Retrieved from
https://tallgrassbiologics.com/services/
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Purification of Antigen-Specific IgY via Freeze-Thaw
Yolks were processed according to Stage I of the protocol described by Petr
Hodek.50 Yolks were diluted with seven volumes of tap water and brought to a pH of 5.0
using 1.0 N HCl. This was done in 1-gallon containers, with each container consisting of
500 mL yolk, 3 L water, and 36 mL 1.0 N HCl. A pH probe was used to verify the pH of
each aliquot after mixing. This solution was frozen overnight at -18°C and thawed the
following day at room temperature.
Upon thawing, the solution separated into two distinct layers: an upper aqueous
layer containing the IgY (mostly transparent) and a lower viscous layer, containing lipids
and other waste (orange). The upper aqueous layer was removed with a pipette
connected to a transfer pump with the bottom lipid layer being discarded. The aqueous
layer was labelled and referred to as “freeze-thaw” or “Diluted and Clarified Egg Yolks”.
The Diluted and Clarified Egg Yolks were then poured through cheese cloth and a mesh
wire filter to remove any remaining large lipid particles.

Figure 2-3. Diluted and Clarified Egg Yolks after lipid layer is discarded. Note the off-yellow, cloudy
color.
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Next, the Diluted and Clarified Egg Yolks were concentrated with the MiniKros
Hollow Fiber Filter Module (P/N: N04-E030-05-N; Media/Rating: mPES / 30 k; Surface
Area: 5400 cm^2; Max.Op.Pressure 30 psig (2 bar); SN: 3303990-07/18-002) using the
Masterflex Industrial/Process Easy-LoadTM Pump Head (model 7529-30). The pump was
calibrated to a flow rate of 700 mL/minute.

Figure 2-4. Filtering apparatus used to concentrate Diluted and Clarified Egg Yolks into Hollow Fiber
Concentrated Antibody.

The filter concentrated the antibody solution until only foam remained in the line,
and this concentrate was added to an equal volume of PBS and stored at -80°C. This
final 1:1 solution of concentrate and PBS was labelled and referred to as “Hollow Fiber
Concentrated Antibody”. The filtrate from the permeate line was also saved and labelled
as “Hollow Fiber Filtrate”. It should be noted that this highly concentrated antibody
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separates into two distinct layers when refrigerated and should be shaken vigorously to
homogenize before use.

Figure 2-5. Hollow Fiber Concentrated DWV and P. larvae IgY and corresponding filtrate, respectively.

Purification of Antigen-Specific IgY via Exalpha EggsPress Kit
For use as a standard with which to compare the Hollow Fiber Concentrated
Antibody, a small aliquot of yolk was also processed via the EggsPress IgY Purification
Kit from Exalpha. This kit offers an efficient way to purify IgY from the egg yolks of
immunized hens for research purposes without the loss of antibody activity.57 100 mL of
yolks were added to a 1 L jar along with 5 volumes of cold Reagent A and gently
stirred.57 This solution was incubated for two hours in the refrigerator. After incubation,
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the solution was shaken for homogenization and then centrifuged at 4,000 x g for 20
minutes at 4°C. The resulting colorless supernatant (400 mL) was transferred into a
graduated cylinder and mixed slowly with an equal volume of Reagent B, stirring for two
minutes.57 This suspension was then incubated a second time in the refrigerator for two
hours. After incubation, the suspension was shaken to homogenize and centrifuged at
4,000 x g for 20 minutes at 4°C. After this centrifugation, the supernatant was discarded.
10 mL PBS was added to the first centrifuge tube, pipetted up and down to dissolve the
pellet, and then transferred to the successive centrifuge tube, a process that was repeated
until the pellets from all 10 centrifuge tubes were pooled together and suspended in the
same 10 mL of PBS. This entire process was performed on 100 mL of yolks from both
DWV- and P. larvae-vaccinated hens.
IgY ELISA
An indirect enzyme-linked immunosorbent assay (ELISA) was performed to
quantify the amount and activity of antigen-specific IgY in each preparation. Immulon
2HB polystyrene microplates were coated with recombinant VP1, VP2, and VP3 by
incubating plates at 4°C overnight with 100 uL per well of a 50 mM carbonate buffer, pH
9.6, containing 1 ug/mL of each protein.
To begin the assays, plates were emptied and 100 μL of Thermo Fisher
Scientific’s SuperBlock Blocking Buffer was added to each well using a multichannel
pipette. The plates were incubated for one hour at 37°C. Following this first incubation
period, the plates were emptied again and another 100 μL of SuperBlock was added to
each well. Next, 100 μL of primary antibody diluted 1:50 in SuperBlock was added to
row A, pipetted up and down for mixing, and transferred likewise through rows B-H to
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give a series of dilutions. 100 μL was removed and discarded from row H, giving all
wells a final total volume of 100 μL. The plates were then incubated a second time for
one hour at 37°C. A table of the ELISA plate setup showing primary antibodies used and
dilutions is shown below.

Table 2-1. Plate setup and dilutions for IgY ELISA.

A
B
C
D
E
F
G
H

1
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

2
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

3
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

4
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

5
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

6
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

7
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

8
1:100
1:200
1:400
1:800
1:1600
1:3200
1:6400
1:12800

9
Blank
Blank
Blank
Blank
Blank
Blank
Blank
Blank

Primary antibodies for each column are as follows: 1 – DWV EggsPress Kit Aby; 2 – DWV Hollow Fiber
Concentrated Aby; 3 – DWV Hollow Fiber Filtrate; 4 – DWV Diluted and Clarified Egg Yolks; 5 – P.
larvae EggsPress Kit Aby; 6 – P. larvae Hollow Fiber Concentrated Aby; 7 – P. larvae Hollow Fiber
Filtrate; 8 – P. larvae Diluted and Clarified Egg Yolks; 9 – SuperBlock Control (Blank)

Following incubation, plates were emptied and washed three times with 150 μL of
a solution of phosphate buffered saline containing 0.05% tween 20 (PBS-tween) per well.
Anti-chicken IgY horseradish peroxidase (HRP) served as the secondary antibody. This
antibody was diluted 1:1000 in SuperBlock and added at a volume of 100 μL per well.
The plates were then incubated a third time, this time for 30 minutes at 37°C. After
incubation, plates were once again emptied and washed three times with 150 μL of PBS23

tween per well. Immediately following the final wash, 100 μL of SIGMAFASTTM OPD
(o-phenylenediamine dihydrochloride), an HRP substrate, was added to each well and
incubated for 15 minutes at room temperature. After 15 minutes, 100 μL of 1.0 N HCl
was added to each well to halt the reaction. The optical densities of each well were then
read at a wavelength of 460 nm using a Biotek plate reader.
Preparation of P. Larvae Challenge
Paenibacillus larvae was purchased from the American Type Collection
Collection (ATCC 49843). P. larvae was propagated on tryptic soy agar containing 5%
sheep blood at 37°C. Spores were isolated from 5-day cultures by flooding the plates
with 3 mL of ice-cold PBS followed by gentle scraping with a sterile inoculation loop.
Fluids were pipetted to a centrifuge tube and centrifuged at 1,000 x g for 5 minutes to
pellet vegetative cells. The supernatant containing spores was transferred to a new tube.
Preparation of DWV Challenge
A lot of 320 frozen honeybees was purchased from a commercial supplier. Bees
were frozen at -80°C followed by homogenization in a plastic liner containing 80 mL of
PBS (10 mL PBS for every 40 bees) for a final volume of 88 mL. This solution was
centrifuged at 5,000 x g for 10 minutes at 4-8°C. The insoluble orange portion of the
supernatant and pellet were discarded, while the remaining supernatant was spun again at
20,000 x g for 20 minutes at 4-8°C. Again, the floating orange layer and pellet were
discarded. The remaining supernatant was then centrifuged at 75,600 x g (25,000 rpm)
for two hours at 4-8°C. The resulting pellet was suspended in 2 mL PBS, while the
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supernatant was discarded. The temperature during all centrifugation steps should be
held between 4-8°C. The challenge was stored at -80°C until use in larval challenges.
Larval Experiments
To test the effectiveness of the antibody, worker bee larvae were grown in-vitro
according to the protocol described by Daniel Schmehl.58 A frame containing at least
25% eggs and 1st instar larvae was selected from a hive and transported to the lab in an
insulated box. The frame was kept humidified (i.e. draped in wet paper towels) during
transport. Using a Chinese grafting tool, 1st instar larvae were grafted from the brood
cells of the frame into queen cell cups (Mann Lake Ltd. Cat. #QC-520) inserted into each
well of 48-well tissue culture plates. Each queen cup contained 20 μL of Diet A at the
time of grafting. Larvae were fed according to Schmehl’s feeding schedule (see Tables
2-2 and 2-3) with two exceptions: 20 μL of Diet A being administered on day 2 rather
than 20 μL of Diet B; and an additional 10 μL of Diet A containing treatment was given
on day 0, post-grafting.58 Larvae receiving challenge received challenge only on day 0,
while larvae receiving antibody received antibody at the desired concentration in each
feeding. Rather than applying feed directly on top of larvae, it was pipetted down the
side of the queen cups to avoid drowning.
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Table 2-2. Percent Composition of Larval Feed

Royal Jelly

Glucose

Fructose

Yeast Extract Water

Diet A

44.25%

5.30%

5.30%

0.90%

44.25%

Diet C

50.00%

9.00%

9.00%

2.00%

30.00%

Antibody and challenge were added at desired concentrations.

Table 2-3. Larval Feeding Schedule

Day 0

Day 1

20 μL Diet A None
10 μL Diet A
+ Treatment

Day 2

Day 3

20 μL Diet A

30 μL Diet C

Day 4
40 μL Diet C

Day 5
50 μL Diet C

Days correspond to time since grafting. Antibody groups were fed antibody in each feeding, while
challenge groups were only fed challenge on day 0.

Grafted larvae were then placed in a plastic container containing a supersaturated
salt solution consisting of 80 g K2SO4, 200 g NaCl, and 500 mL H2O and incubated at
35°C in a humidified incubator. For both the DWV and P. larvae models, there was a
negative control group receiving only feed and three Hollow Fiber Concentrated
Antibody control groups without challenge (1:25 dilution, 1:100 dilution, and 1:400
dilution) to test for toxicity. Both models also had a positive control group receiving
either DWV stock diluted 1:10 in larval feed (Type A DWV at 107 genome copies per
26

larvae) or P. larvae spore challenge material diluted 1:10 in larval feed. Additionally,
each model also had three final groups that received a 1:10 dilution of challenge material
and one of the three aforementioned dilution levels of pathogen-specific Hollow Fiber
Concentrated Antibody.
Mortality assessment and feeding occurred every 24 hours post-grafting. Dead
larvae were identified by a combination of discoloration, a sunken appearance beneath
the feed, and grossly apparent stunted growth relative to healthy control group
individuals. All dead larvae were removed daily, sorted by treatment group, and frozen
for molecular analysis. Larvae from each treatment group were separated into “live” and
“dead” pools. Larvae were considered “live” only if they survived until the experiment’s
endpoint.
Note: It is critical to use only 1st instar larvae for both DWV and P. larvae challenges, as
larvae are most susceptible to these pathogens during the first 24-48 hours of life, posthatching.
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Figure 2-6. In-vitro A. mellifera larvae in queen cups during DWV challenge experiment. Dead larvae
have been removed and pooled for further analysis.

DWV Real-Time PCR
At the conclusion of each DWV in-vitro larval experiment, larvae from each
treatment group were tested for the presence of DWV using QuantiTect SYBR Green
Real-Time RT-PCR Kit. Each pool of larvae was added to two volumes of PBS, crushed
using a pipette tip, and vortexed for several seconds. 0.2 mL of each sample was added
to a micro-centrifuge tube and spun at 2,000 x g for 5 minutes.
100 μL of each resulting supernatant was added to 100 μL of Thermo Fisher
Scientific’s PrepManTM Ultra and vortexed. These tubes were placed on a heat block at
98°C for 10 minutes. After heating, samples were micro-centrifuged at 20,627 x g
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(15,000 rpm) for 10 minutes. The resulting supernatants were used as the template RNA
samples for PCR. The following volumes (given per sample) were combined to create
the master mix: 0.5 μL PAN DWV Forward primer, 0.5 μL PAN DWV Reverse primer,
12.5 μL 2X QuantiTect SYBR Green RT-PCR Master Mix, 8.75 μL nuclease-free water,
0.25 μL QuantiTect RT Mix, and 2.5 μL template RNA sample (total volume/well = 25
μL). Thermocycler settings are given in Table 2-4.

Table 2-4. Thermocycler Protocol Used for SYBR Green RT-PCR of DWV

Cycle

Repeats

Step

Dwell Time

Set Point (°C)

1

1

1

30:00

50.0

2

1

1

15:00

95.0

3

44

1

00:15

94.0

2

00:30

55.0

3

00:30

72.0

P. Larvae Plating
At the conclusion of each P. larvae in-vitro larval experiment, larvae were sorted
by treatment groups and further separated into “live” and “dead” pools. Each set of
larvae was pooled in a tube and centrifuged at 1,000 x g for one minute to bring the
minimal volume of larval remains to the bottom of the tube. The remains were then
suspended in two volumes of PBS and crushed using a pipette tip. The tubes were spun
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again at 1,000 x g for one minute to remove large and insoluble debris. Using the
resulting supernatant, a series of four dilutions in PBS was prepared for each sample: 102

, 10-4, 10-6, and 10-8. 100 μL of each dilution for each treatment was added to a tryptic

soy broth + 5% sheep blood agar plate (BAP) and incubated at 37°C. Colony counts
were taken on days two and five.
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CHAPTER THREE
Results

IgY Concentration
Concentrated IgY solutions with anti-DWV and anti-P. larvae specificity were
successfully created by processing the egg yolks of white leghorn chickens vaccinated
against each respective antigen. It was estimated that each egg provides approximately
16.67 mL of yolk and 11.05 mL of Hollow Fiber Concentrated Antibody. Each 100 mL
batch of egg yolks purified using the Exalpha EggsPress Kit yielded a final volume of 17
mL: 10 mL PBS and 7 mL of suspended antibody pellets.
The antibody titer was qualitatively determined by utilizing indirect enzymelinked immunosorbent assay (ELISA), with VP1, VP2, and VP3 acting as the antigens for
the anti-DWV ELISA and P. larvae as the antigen for the anti-P. larvae ELISA. For
each model, Diluted and Clarified Egg Yolks from hens non-immunized for the antigen
of interest were run as a control. The antibody titers for the various antibody preparations
are illustrated below with absorbance readings charted as a function of dilution.
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Anti-P. larvae ELISA

1.8

DWV - Diluted and Clarified Egg
Yolks

1.6
P. Larvae - Diluted and Clarified
Egg Yolks

Absorbance

1.4
1.2

1

P. Larvae - EggsPress Kit
Antibody

0.8
0.6

P. Larvae - Hollow Fiber
Concentrated Antibody

0.4
0.2
0
100

1000

10000

P. Larvae - Hollow Fiber Filtrate

Dilution (log scale)

Figure 3-1. Enzyme-linked immunosorbent assay data for processed P. larvae-specific antibody. 1:250
dilution was used for primary antibody (various preparations of IgY) and 1:5000 dilution was used for
secondary antibody (horseradish peroxidase). P. larvae was the antigen. Anti-DWV Diluted and Clarified
Egg Yolks (non-immunized for P. larvae) were run as a control. “Kit Purified” refers to antibody
concentrated using the Exalpha EggsPress IgY Purification Kit, which was used as a standard. “Filtrate”
refers to the waste from the permeate line during filtration.

Anti-DWV ELISA

1.6

DWV - Diluted and Clarified
Egg Yolks

1.4
DWV - EggsPress Kit Antibody

Absorbance

1.2
1

DWV - Hollow Fiber
Concentrated Antibody

0.8
0.6
0.4

DWV - Hollow Fiber Filtrate

0.2
0
100

1000

10000

P. Larvae - Diluted and
Clarified Egg Yolks

Antibody Dilution (logarthmic scale)

Figure 3-2. Enzyme-linked immunosorbent assay data for processed DWV-specific antibody. 1:50
dilution was used for primary antibody (various preparations of IgY) and 1:1000 dilution was used for
secondary antibody (horseradish peroxidase). VP1, VP2, and VP3 proteins acted as the antigen. P. larvae
samples were run as controls. “Kit Purified” refers to antibody concentrated using the Exalpha EggsPress
IgY Purification Kit, which was used as a standard. “Filtrate” refers to the waste from the permeate line
during filtration.
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In both the anti-P. larvae and anti-DWV models, Hollow Fiber Concentrated
Antibody demonstrated a much higher antibody titer than its unfiltered counterpart, the
Diluted and Clarified Egg Yolks. The Hollow Fiber Concentrated Antibody also
demonstrated a much higher antibody titer than the Hollow Fiber Filtrate, providing
evidence that the filtering process was effective and that it efficiently captured the IgY.
Additionally, the Hollow Fiber Concentrated Antibody either surpassed (in the case of
the anti-DWV model) or nearly attained (in the case of the anti-P. larvae model) the
standard of the Exalpha EggsPress IgY Purification Kit. In both models, the non-specific
Diluted and Clarified Egg Yolks functioning as a control showed very low titers of
antibodies that demonstrated activity against the pathogen of interest.
P. Larvae Challenge Model Larval Mortality
The P. larvae larval challenge model was carried out for three days. All antibody
administered in this model was Hollow Fiber Concentrated Antibody. The daily
mortality data is displayed in the following table.
Note: The P. larvae model used the antibody-only controls from the DWV model, as all
component concentrations and preparation procedures of the solutions were entirely
identical.
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Table 3-1. P. larvae challenge model daily mortality (number of new larval deaths per day)

Treatment Group
Control (Feed Only)
1:25 DWV Aby
1:100 DWV Aby
1:400 DWV Aby
1:10 P.L. Spores
1:25 P.L. Aby / 1:10 P.L. Spores
1:100 P.L. Aby / 1:10 P.L. Spores
1:400 P.L. Aby / 1:10 P.L. Spores

Day 1
0
0
0
0
0
0
0
0

Day 2
1
0
0
1
4
2
1
2

Day 3
0
0
0
0
20
16
3
12

Total
1
0
0
1
24
18
4
14

These results revealed that among larvae receiving P. larvae spore challenge, those
also receiving a 1:100 dilution of P. larvae aby (1:100 P. larvae Aby / 1:10 P. larvae
spores) displayed by far the lowest mortality rates. Therefore, the 1:100 P. larvae Aby
dilution was considered the minimum protective dosage to significantly reduce P. larvaerelated mortality. Only the following four treatment groups were considered for
statistical analysis: Control (Feed Only), 1:100 DWV aby, 1:10 P. larvae spores, and
1:100 P. larvae aby / 1:10 P. larvae spores. The cumulative mortality percentages of
these four groups throughout the three-day duration of this experiment is shown in Figure
3-3.
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P. Larvae Cumulative % Mortality
100.00

% Cumulative Mortality

Control (Feed Only)

100.00

90.00
80.00
70.00

1:100 DWV Aby

60.00
16.67

50.00

1:10 P.L. Spores

40.00

4.17

30.00

0.00

20.00

1:100 P.L. Aby / 1:10
P.L. Spores

10.00
0.00
1

2

3

Day

Figure 3-3. Cumulative larval mortality percentages through three-day P. larvae challenge model. Data
labels display total group mortality percentages at the experiment’s endpoint (t = 3 days).

The data was analyzed using the Kaplan-Meier method for survival analysis.59 Using
this model, it was assumed that the probability of individuals being censored was the
same for all groups and did not affect the outcome, survival probabilities were the same
for all individuals in all groups, and the event of interest (death) occurred at the specified
times.59 The Kaplan-Meier survival curves with 95% confidence intervals for each group
are displayed below. Larvae surviving beyond day 3 are considered right-censored and
are therefore indicated by a tick mark.
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Figure 3-4. Survival curves for P. larvae model with 95% confidence intervals. Tick marks represent
censored individuals (larvae that survived to endpoint).
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The survival data of the four groups was then compared using the log-rank test, which
operates under the same assumptions as the Kaplan-Meier method. The null hypothesis
(H0) for each comparison was that the mortality rates of the two groups being compared
had no significant difference over the three-day experiment. The alternative hypothesis
(H1) was that one of the groups had a significantly higher mortality rate than the other
over the three-day experiment. One degree of freedom (df=1) and a confidence level of
95% was utilized (α = 0.05), meaning a p-value of less than 0.05 was sufficient to reject
the null and imply a significant difference in mortality.
Four separate comparisons of mortality rates were made between groups. The
first compared the control (feed only) group and the 1:100 DWV aby group to test for
potential antibody toxicity. Log-rank analysis gave a p-value of 0.3, failing to reject the
null and showing no significant difference between mortality rates. No difference in
these mortality rates suggests that the 1:100 dilution of antibody was nontoxic.
The next comparison was between the control (feed only) group and the 1:10 P.
larvae spore challenge group. This comparison functioned to test for pathogenicity of the
P. larvae challenge material, and it yielded a p-value of 6e-10. This result rejected the
null and implied a significantly higher mortality in the group receiving P. larvae spore
challenge than in the control group receiving feed only. It was therefore assumed that the
P. larvae spore challenge material was responsible for inducing a higher rate of mortality
than was seen in the control group.
The third comparison was between the 1:10 P. larvae spore challenge group and the
1:100 P. larvae aby / 1:10 P. larvae spore treatment group. This comparison tested to see
if larvae receiving antibody in addition to challenge material survived at a significantly
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higher rate than larvae receiving only challenge material. This log-rank comparison
returned a p-value of 4e-8, rejecting the null and suggesting that larvae receiving a 1:100
dilution of P. larvae-specific antibody in their feed in addition to the DWV challenge
material had a significantly lower mortality rate and higher rate of survival than larvae
receiving only challenge.
The last comparison was between the control (feed only) group and the 1:100 P.
larvae aby / 1:10 P. larvae spore treatment group. This comparison tested for a potential
difference in the mortality rate of larvae challenged with P. larvae spores and treated
with antibody compared to larvae receiving no challenge or antibody. This log-rank
analysis returned a p-value of 0.2, failing to reject the null hypothesis and implying that
the larvae receiving both challenge and antibody treatment did not die at a higher rate
than larvae receiving only feed in the control group.
P. Larvae Challenge Model CFU Evaluation
Colony counts from the dilution series plated with the prepared larvae from the P.
larvae challenge model were taken on days 2 and 5 to calculate CFU/mL. The results are
summarized in Figure 3-5.
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P. Larvae CFU/mL
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Figure 3-5. CFU/mL values of larvae from P. larvae challenge model.

The CFU data closely matched the mortality data; the feed-only controls were
negative for P. larvae cells and the challenge group had the most viable P. larvae cells.
More significantly, however, of the treatment groups receiving both challenge and anti-P.
larvae IgY, the group receiving the 1:100 dilution of antibody demonstrated the fewest
CFU/mL. The 1:100 P. larvae Aby / 1:10 P. larvae spores treatment group had both the
lowest mortality rate and lowest CFU/mL value. This alignment with the mortality data
reinforces the conclusion that the 1:100 dilution of anti-P. larvae IgY corresponds to the
minimum protective dosage.
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DWV Challenge Model Larval Mortality
The DWV larval challenge model was carried out for five days. All antibody
administered in this model was Hollow Fiber Concentrated Antibody. The daily
mortality data is displayed in the following table.
Table 3-2. DWV challenge model daily mortality (number of new larval deaths per group per day)

Treatment Group (n=24)
Control (Feed Only)
1:25 DWV Aby
1:100 DWV Aby
1:400 DWV Aby
1:10 DWV
1:25 DWV Aby / 1:10 DWV
1:100 DWV Aby / 1:10 DWV
1:400 DWV Aby / 1:10 DWV

Day 1 Day 2 Day 3 Day 4
Day 5
0
1
0
2
3
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
1
2
15
0
0
2
0
8
0
1
0
2
4
0
0
0
1
5

Total
6
0
0
1
19
10
7
6

This data demonstrates that among larvae receiving DWV challenge, those also
receiving a 1:100 dilution of DWV aby (1:100 DWV Aby / 1:10 DWV) displayed among
the lowest mortality rates. Therefore, the 1:100 DWV Aby dilution was considered the
minimum protective dosage to significantly reduce DWV-related mortality. The
following four treatment groups were considered for statistical analysis: Control (Feed
Only), 1:100 DWV Aby, 1:10 DWV, and 1:100 DWV Aby / 1:10 DWV. The cumulative
mortality percentages of these four groups throughout the duration of the experiment is
visualized in Figure 3-6.
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Figure 3-6. Cumulative larval mortality percentages through five-day DWV challenge model. Data labels
display total group mortality percentages at the experiment’s endpoint (t = 5 days).

The data was then analyzed using the Kaplan-Meier method for survival
analysis.59 Using this model, it was assumed that the probability of individuals being
censored was the same for all groups and did not affect the outcome, survival
probabilities were the same for all individuals in all groups, and the event of interest
(death) occurred at the specified times.59 The Kaplan-Meier survival curves with 95%
confidence intervals for each group are displayed below. Larvae surviving beyond day 5
are considered right-censored and are indicated by a tick mark.
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Figure 3-7. Survival curves for DWV model with 95% confidence intervals. Tick marks represent
censored individuals (larvae that survived to endpoint).
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The survival data of the four groups was then compared using the log-rank test, which
operates under the same assumptions as the Kaplan-Meier method. The null hypothesis
(H0) for each comparison was that the mortality rates of the two groups being compared
had no significant difference in mortality rate over the five-day experiment. The
alternative hypothesis (H1) was that one of the groups had a significantly higher mortality
rate than the other over the five-day experiment. One degree of freedom (df=1) and a
confidence level of 95% was utilized (α = 0.05), meaning a p-value of less than 0.05 was
sufficient to reject the null and imply a significant difference in mortality.
Four mortality comparisons were made between groups. The first comparison was
between the control (feed only) group and the 1:100 DWV aby group to test for antibody
toxicity. Log-rank analysis gave a p-value of 0.01, implying that the group receiving
antibody had a significantly lower mortality than the feed-only controls. However, as
zero larvae died in the 1:100 DWV aby group, it was assumed that there was no antibody
toxicity.
The next comparison was between the control (feed only) group and the 1:10 DWV
challenge group. This comparison was made to test for pathogenicity of the DWV
challenge material and it yielded a p-value of 0.001. This result was sufficient to reject
the null and implied a significantly higher mortality in the group receiving DWV
challenge than in the control group receiving feed only. It was therefore assumed that the
DWV challenge material was responsible for the difference in mortality rates.
The third comparison was between the 1:10 DWV challenge group and the 1:100
DWV Aby / 1:10 DWV challenge treatment group. This tested to see if larvae receiving
both antibody and challenge fared better than larvae receiving only challenge. This log43

rank comparison returned a p-value of 0.002, rejecting the null and implying that larvae
receiving a 1:100 dilution of antibody in their feed in addition to the DWV challenge
material had a significantly lower mortality rate than larvae receiving only challenge.
The final comparison was between the control (feed only) group and the 1:100 DWV
Aby / 1:10 DWV treatment group. This comparison aimed to detect if larvae challenged
with DWV and treated with antibody fared any worse than larvae receiving no challenge
or antibody. This log-rank analysis returned a p-value of 0.8, failing to reject the null
hypothesis and implying that larvae receiving both challenge and antibody treatment did
not die at a higher rate than larvae receiving only feed in the control group.
DWV Challenge Model RT-PCR Evaluation
To confirm the mortality data on a molecular level, real-time reverse transcriptase
PCR was performed on all larvae, both dead and alive, in all groups at the conclusion of
the five-day DWV model. Overall Ct values for each treatment group were calculated by
determining the weighted Ct value of the dead and alive larvae in that group according to
the following formula: 𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝐶𝑡 =

𝐶𝑡𝑑𝑒𝑎𝑑 (# 𝑙𝑎𝑟𝑣𝑎𝑒 𝑖𝑛 𝑙𝑜𝑡)+ 𝐶𝑡𝑎𝑙𝑖𝑣𝑒 (# 𝑙𝑎𝑟𝑣𝑎𝑒 𝑖𝑛 𝑙𝑜𝑡)
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The results are summarized in Table 3-3 and Figure 3-8.
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Table 3-3. SYBR Green RT-PCR Ct Values of Larvae from DWV Model

Group
Control (Feed Only)
1:25 DWV Aby
1:100 DWV Aby
1:400 DWV Aby
1:10 DWV
1:25 DWV Aby / 1:10 DWV
1:100 DWV Aby / 1:10 DWV
1:400 DWV Aby / 1:10 DWV

Weighted Ct Value
37.100
37.100
37.100
37.190
25.270
32.951
29.229
28.525

SYBR Green RT-PCR DWV Ct Values
40
35

Ct Value

30
25
20
15
10
5
0

Control (Feed 1:25 DWV
Only)
Aby

1:100 DWV
Aby

1:400 DWV
Aby

1:10 DWV

1:25 DWV
Aby / 1:10
DWV

1:100 DWV
Aby / 1:10
DWV

1:400 DWV
Aby / 1:10
DWV

Figure 3-8. DWV RT-PCR results from DWV larval challenge model. The reported Ct values represent
weighted averages of live and dead larvae pools from each experimental treatment group.

The RT-PCR results closely align with the DWV challenge model mortality data.
The feed-only and antibody controls were negative for DWV, while the DWV challengeonly group returned the lowest Ct value – corresponding to the highest DWV titer. Of
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the groups receiving both DWV challenge and anti-DWV IgY, the Ct value is directly
proportional (and the viral titer is inversely proportional) to the volume of IgY
administered to each respective group. This finding suggests that as more anti-DWV IgY
is administered, more DWV viral particles are neutralized.
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CHAPTER FOUR
Discussion

The results of the presented research suggest that passive pathogen-specific IgY
can be effectively generated by vaccinating white leghorn chickens against various
antigens and that these antibodies are entirely safe and nontoxic to A. mellifera. At all
dosages tested in the larval trials, none of the control groups receiving Hollow Fiber
Concentrated Antibody demonstrated significantly higher rates of mortality than the feedonly control group, suggesting no toxicity of the antibody in either model. Interestingly,
in the DWV model, a significantly lower mortality rate was detected in the antibody
controls than in the feed only controls. Given that RT-PCR showed the controls to be
negative for DWV, it is not plausible for this difference to be explained by the presence
of endemic DWV in the colony from which tested larvae were grafted. This unexpected
finding may suggest that the administered IgY has additional benefits during
development that were beyond the scope of this study.
The results also demonstrate that pathogen-specific antibodies are highly effective
for the treatment of DWV and P. larvae, two of the most detrimental pathogens facing A.
mellifera. Larvae receiving a 1:100 dilution of anti-DWV Hollow Fiber Concentrated
Antibody in addition to DWV challenge demonstrated a statistically significant 50%
reduction in mortality compared to larvae receiving DWV challenge alone. No
significant difference was found between the mortality of feed only control larvae and the
mortality of larvae receiving both challenge and anti-DWV IgY. This suggests that even
when challenged, larvae treated with Hollow Fiber Concentrated Antibody are no more
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likely to die than larvae subjected to the feed only control condition. This result was
supported by RT-PCR data that reveals a clear inversely proportional relationship
between the quantity of antibody administered and DWV titer.
Similar findings were derived from the P. larvae model. Larvae receiving a 1:100
dilution of anti-P. larvae Hollow Fiber Concentrated Antibody in addition to P. larvae
challenge demonstrated a statistically significant 83% reduction in mortality compared to
larvae receiving only P. larvae challenge. Likewise, no significant difference was found
between the mortality of feed-only control larvae and the mortality of larvae receiving
both challenge and anti-P. larvae IgY. This suggests that even when challenged, larvae
treated with Hollow Fiber Concentrated Antibody are no more likely to die than larvae
subjected to the feed only control condition. This result was largely supported by the
CFU/mL data collected on these larvae. Among the treatment groups receiving
challenge, the CFU/mL value was lowest in the group additionally receiving a 1:100
dilution of Hollow Fiber Concentrated Antibody, matching the mortality data. CFU/mL
values were unexpectedly high in the treatment groups receiving challenge and either
1:25 antibody or 1:400 antibody. For the 1:400 antibody group, it was surmised that
these results were due to the dosage being below the minimum protective dosage. In the
1:25 antibody group, it was speculated that elevated antibody levels led to an increased
titer of antibody-antigen complex, which may have contributed to pathophysiological
effects contributing to larval death and ultimately allowing for further propagation of P.
larvae post-mortem.
Modern honeybees face a plethora of risk factors and threats to their health and
ultimate survival. Of the limited options currently available for CCD prevention and/or
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treatment, most are focused exclusively on the control of Varroa. Controlling mite levels
is important, but these options alone offer limited flexibility and benefits. Given the
multifactorial nature of CCD and the many pathogens that contribute to it, multipronged
treatment methods are likely to be the most effective. Aside from DWV, at least 22 other
honeybee viruses have been identified, and eight of these are considered to cause severe
or lethal illness, including Kakugo Virus (KV), Israeli Acute Paralysis Virus (IAPV),
Sacbrood Virus (SBV), Black Queen Cell Virus (BQCV), Kashmir Bee Virus (KBV),
Acute Bee Paralysis Virus (ABPV), and Chronic Bee Paralysis Virus (CBPV). 60 With the
exception of CBPV, all of these viruses share many conserved and consensus sequences
within their genomes and have several morphological similarities such as a 20-30 nm
diameter and an isometric protein capsid consisting of 60 repeated protomers that contain
the VP1, VP2, and VP3 subunits.60 All these viruses also have similar horizontal and
vertical routes of transmission. Given these similarities, it seems probable that the
technology described in this research could be effectively applied to these viruses as well.
While these additional viruses were beyond the scope of this study, further testing is
necessary to determine how broadly this technology can be applied.
This technology also has the potential to be effective in treating other species
within the Apidae family, including not only other members of the Apis (honeybee)
genus, but also of the Bombus (bumblebee) genus. Much like Apis, Bombus also plays an
important role in the pollination of natural flora and is occasionally used commercially in
greenhouses (usually Bombus terrestris).61 Bombus is afflicted by many of the same
pathogens as Apis, most notably DWV, which has the same deleterious effects on both
honeybees and bumblebees. Furthermore, there is evidence that domesticated Apis is
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responsible for spreading pathogens to native Bombus.61 As domesticated honeybees
continue to be used in new regions and at higher rates for commercial purposes, an
increased potential arises for the transmission of viruses to the native Bombus species.
Pathogen-specific antibody treatments could therefore benefit Bombus not only by
possibly being effective when directly applied to Bombus colonies, but also by
neutralizing these antibodies in the domesticated Apis colonies from which these
pathogens are spread.
The potential for an antibody treatment specifically formulated to target the most
prevalent pathogens in a given apiary or region brings with it the necessity for efficient
and affordable diagnostic testing to be made available to beekeepers. Monitoring the
levels of various pathogens within the herd is a common practice in the husbandry of
swine, cattle, poultry, etc. due to the availability of effective treatment options. The
development of similar pathogen-specific treatment options for honeybees should bring
about a paradigm shift in the methodology and philosophy of beekeeping. Cost-effective
multiplex PCR panels may be developed along with a means of hive sample collection
(i.e. honeycomb, larval specimen, worker specimen, etc.) and transport to allow for
efficient and thorough diagnostic analysis and diagnosis. Additionally, increased
knowledge and understanding of the nature and mechanisms of these pathogens is likely
to result from higher surveillance of hives. Metagenomic sequencing of such samples
also has the potential to further reveal novel pathogens within the sampled colonies.
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CHAPTER FIVE
Conclusion

Honeybee populations are in a precarious position, and the discouraging trends in
their numbers and health are likely to continue without a focused effort by beekeepers to
mitigate some of the factors contributing to CCD in their apiaries. While individual
apiarists cannot assess factors such as reduced plant diversity and climate change on their
own, they should be committed to taking steps to reduce the levels of dangerous and
potentially lethal pathogens inside their colonies. DWV and P. larvae are currently two
of the most detrimental pathogens to overall hive health and are known to initiate and/or
accelerate the onset of CCD.
The production of viable, pathogen-specific IgY antibodies is possible when avian
species are vaccinated for a given antigen and subsequently confer these antibodies to the
yolks of the eggs they lay through passive immunity. Producing antibodies for
biomedical purposes in this manner is far more cost-effective, efficient, and sustainable
than many of the far more invasive methods currently employed for IgG collection. In
addition to the ease with which these antibodies can be produced and concentrated, there
is also mounting evidence that they are safe and effective for use in treating non-avian
pathogens in non-avian species, such as DWV and P. larvae in A. mellifera.
The effectiveness with which IgY can treat pathogens in honeybees is an
unexpected finding that holds lots of promise for the future of honeybee health, apiary
revenues, and the overall success of the agriculture industry as it struggles to continually
meet the growing global demand for food supply. The introduction of effective
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treatments for DWV, P. larvae, and the potential for creation of IgY treatments for
additional honeybee pathogens could revolutionize the future of honeybee health and
beekeeping. Supplementing colonies with pathogen-specific IgY can offer the necessary
protection to help compensate for honeybees’ limited immune systems and ultimately
help stabilize the shrinking honeybee population – cause for great encouragement and
enthusiasm among apiarists and bee enthusiasts alike.
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